肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
Cancer Research and Clinic
2015年
10期
683-686
,共4页
范瑞华%张铁成%姚榕%黄明德
範瑞華%張鐵成%姚榕%黃明德
범서화%장철성%요용%황명덕
食管肿瘤%多西他赛%顺铂%放射疗法%老年人
食管腫瘤%多西他賽%順鉑%放射療法%老年人
식관종류%다서타새%순박%방사요법%노년인
Esophageal neoplasms%Docetaxel%Cisplatin%Radiotherapy%Elderly
目的 探讨小剂量多西他赛+顺铂(TP)每周方案化疗联合放疗治疗老年人局部晚期食管癌的临床疗效.方法 回顾性分析65例老年局部晚期食管癌患者的临床资料,其中TP方案化疗联合放疗(放化组)33例,单纯放疗(单放组)32例.两组放疗均采用三维适形放疗(3D-CRT).放化组采用多西他赛40 mg/次+顺铂40 mg/次,于放疗第1、8、15、22、36天使用.结果 放化组有效(完全缓解+部分缓解)29例,有效率为87.8％;单放组有效21例,有效率为65.6％,两组差异有统计学意义(P＜0.05);中位疾病进展时间放化组为5.5个月,单放组为4.3个月,两组差异有统计学意义(P＜0.05);1年生存率放化组为69.6％,单放组为59.3％,两组差异无统计学意义(P＞0.05).胃肠道反应、放射性食管炎等发生率放化组均高于单放组(P＜0.05).结论 小剂量TP方案同步放化疗治疗老年人局部晚期食管癌疗效显著,不良反应可耐受.
目的 探討小劑量多西他賽+順鉑(TP)每週方案化療聯閤放療治療老年人跼部晚期食管癌的臨床療效.方法 迴顧性分析65例老年跼部晚期食管癌患者的臨床資料,其中TP方案化療聯閤放療(放化組)33例,單純放療(單放組)32例.兩組放療均採用三維適形放療(3D-CRT).放化組採用多西他賽40 mg/次+順鉑40 mg/次,于放療第1、8、15、22、36天使用.結果 放化組有效(完全緩解+部分緩解)29例,有效率為87.8％;單放組有效21例,有效率為65.6％,兩組差異有統計學意義(P＜0.05);中位疾病進展時間放化組為5.5箇月,單放組為4.3箇月,兩組差異有統計學意義(P＜0.05);1年生存率放化組為69.6％,單放組為59.3％,兩組差異無統計學意義(P＞0.05).胃腸道反應、放射性食管炎等髮生率放化組均高于單放組(P＜0.05).結論 小劑量TP方案同步放化療治療老年人跼部晚期食管癌療效顯著,不良反應可耐受.
목적 탐토소제량다서타새+순박(TP)매주방안화료연합방료치료노년인국부만기식관암적림상료효.방법 회고성분석65례노년국부만기식관암환자적림상자료,기중TP방안화료연합방료(방화조)33례,단순방료(단방조)32례.량조방료균채용삼유괄형방료(3D-CRT).방화조채용다서타새40 mg/차+순박40 mg/차,우방료제1、8、15、22、36천사용.결과 방화조유효(완전완해+부분완해)29례,유효솔위87.8％;단방조유효21례,유효솔위65.6％,량조차이유통계학의의(P＜0.05);중위질병진전시간방화조위5.5개월,단방조위4.3개월,량조차이유통계학의의(P＜0.05);1년생존솔방화조위69.6％,단방조위59.3％,량조차이무통계학의의(P＞0.05).위장도반응、방사성식관염등발생솔방화조균고우단방조(P＜0.05).결론 소제량TP방안동보방화료치료노년인국부만기식관암료효현저,불량반응가내수.
Objective To investigate the efficacy and toxicity of low dose of docetaxel and cisplatin (TP) combined with radiotherapy in the treatment of elderly patients with esophageal cancer.Methods The data of 65 elderly patients with esophageal cancer were studied retrospectively, including 33 patients treated by TP combined with radiotherapy (chemoradiotherapy group) and 32 patients by radiotherapy only (radiotherapy group).Patients in both groups received 3D conventional radiotherapy (3D-CRT).In chemoradiotherapy group, 40 mg/1f docetaxel and 40 mg/1f cisplatin were administered once a week on the 1st, 8th, 15th, 22th, 36th day of five successive weeks.Results In chemoradiotherapy group and radiotherapy group, the response (CR+RR) rates were 87.8 ％ (29/33) and 65.6 ％ (21/32), respectively (P ＜ 0.05), the median TTPs were 5.5 months and 4.3 months, and the difference had statistically significant (P ＜ 0.05).The 1-year survival rate was 69.6 ％ and 59.3 ％ in chemoradiotherapy group and radiotherapy group, respectively, and there was no statistically significant difference between both groups (P ＞ 0.05).The incidences of esophagitis and gastrointestinal tract were slightly higher in chemoradiotherapy group than those in radiotherapy group (P ＜ 0.05).Conclusion Concurrent radiotherapy and chemotherapy with low dose TP can treat effectively esophageal cancer in elderly patients with the tolerable toxic reactions.
